Gene therapy using HVJ-liposomes: The best of both worlds?

Molecular Medicine Today

Volumn 5, Issue 7, 1999, Pages 298-303

  Kaneda, Yasufumi ^a   Saeki, Yoshinaga ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; HYBRID PROTEIN; LIPOSOME; VIRUS VECTOR;

CANCER RESEARCH; CYTOTOXICITY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HEART INFARCTION; IMMUNOGENICITY; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; PARAINFLUENZA VIRUS 1; REVIEW; SENDAI VIRUS; SUICIDE GENE; TRANSGENE;

ANIMALS; BRAIN NEOPLASMS; DRUG CARRIERS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; LIPOSOMES; MEMBRANE FUSION; MYOCARDIAL ISCHEMIA; RESPIROVIRUS; VIRAL FUSION PROTEINS;

ANIMALIA; HUMAN HERPESVIRUS 4; HUMAN PARAINFLUENZA VIRUS 1; SENDAI VIRUS;

EID: 0033167922     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01482-3     Document Type: Review

References (41)

1. Anderson W.F. Human gene therapy. Science. 256:1992;808-813.
2. Mulligan R.C. The basic science of gene therapy. Science. 260:1993;926-932.
3. Ledley F.D. Non-viral gene therapy; the promise of genes as pharmaceutical products. Hum. Gene Ther. 6:1995;1129-1144.
4. Friedmann T.et al. Pseudotyped retroviral vectors for study of human gene therapy. Nat. Med. 1:1995;275-277.
5. Naldini L.et al. In vivo gene delivery and stable transduction of nondividing cells by a lentivirus vector. Science. 272:1996;263-267.
6. Okada, Y. (1993) Sendai-virus induced cell fusion, in Methods in Enzymology (Vol. 221) (Duzgnes, N., ed.), pp. 18-41, Academic Press.
7. Kaneda, Y. (1994) Virus (Sendai virus envelopes) mediated gene transfer, in Cell Biology; A Laboratory Handbook (Vol. 3) (Celis, J.E., ed.), pp. 50-57, Academic Press.
8. Kaneda Y., Iwai K., Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 243:1989;375-378.
9. Kaneda Y., Iwai K., Uchida T. Introduction and expression of the human insulin gene in adult rat liver. J. Biol. Chem. 264:1989;12126-12129.
10. Morishita R.et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J. Clin. Invest. 93:1994;1458-1464.
11. Morishita R.et al. Pharmakokinetics of antisense oligonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall; enhanced therapeutic utility for restenosis by HVJ-liposome method. Gene. 149:1994;3-9.
12. Felgner P.L.et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U. S. A. 84:1987;7413-7417.
13. Hirano T.et al. Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Ther. 5:1998;459-464.
14. Caplen N.J.et al. In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. Gene Ther. 2:1995;603-613.
15. Wheeler C.J.et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11454-11459.
16. Saeki Y.et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus); Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. 8:1997;1965-1972.
17. Chander R., Schreier H. Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160. Life Sci. 50:1992;481-489.
18. Wolff J.A.et al. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
19. Li X.K.et al. Prolonged survival of rat liver allografts transfected with Fas-ligand expressing plasmid. Transplantation. 66:1999;1416-1423.
20. Okuyama T.et al. Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system. Gene Ther. 5:1998;1074-1080.
21. Goyal K., Huang L. Gene therapy using DC-Chol liposomes. J. Liposome Res. 5:1995;49-60.
22. Satoh E.et al. Efficient gene transfection by Epstein-Barr-virus based vectors coupled with cationic liposome and HVJ-liposome. Biochem. Biophys. Res. Commun. 238:1997;795-799.
23. Yonemitsu Y.et al. HVJ (Sendai virus)-cationic liposomes; a novel and potentially effective liposome-mediated gene transfer technique to the delivery to the airway epithelium. Gene Ther. 4:1997;631-638.
24. Yonemitsu Y.et al. HVJ (Sendai virus) liposome-mediated gene transfer: current status and future perspectives. Int. J. Oncol. 12:1998;1277-1285.
25. Lindahl T.et al. Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J. Mol. Biol. 102:1976;511-530.
26. Lupton S., Levine A.J. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus derived plasmids in human cells. Mol. Cell Biol. 5:1985;2533-2542.
27. Yates J.L., Warren N., Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature. 313:1985;812-815.
28. Calos M.P. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet. 12:1996;463-467.
29. Saeki Y., Wataya-Kaneda M., Tanaka K., Kaneda Y. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ-liposomes. Gene Ther. 5:1998;1031-1037.
30. Dzau V.J., Mann M., Morishita R., Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11421-11425.
31. Ordfield E.H.et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4:1993;39-69.
32. Ram Z.et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1997;1354-1361.
33. Freeman S.M.et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274-5283.
34. Miyao Y.et al. Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. J. Neurosci. Res. 36:1993;472-479.
35. Mabuchi E.et al. Gene delivery by HVJ-liposome in the experimental gene therapy of murine glioma. Gene Ther. 4:1997;768-772.
36. Billups K.L., Palladino M.A., Hinton B.T., Shirley J.L. Expression of E-selectin mRNA during ischemia/reperfusion injury. J. Lab. Clin. Med. 125:1995;626-633.
37. Kukielka G.L.et al. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation. 92:1995;1866-1875.
38. Herskowitz A., Choi S., Ansari A.A., Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am. J. Pathol. 146:1995;419-428.
39. Lenardo M., Baltimore D. NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control. Cell. 58:1989;227-229.
40. Morishita R.et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5855-5859.
41. Morishita, R. et-al In vivo transfection of cis element 'decoy' against NFκB binding site prevented myocardial infarction as gene therapy, Nat. Med. 3, 1997 894-899